Ibogamine (12-methoxyibogamine; CAS 467-77-6) is a naturally occurring indole alkaloid isolated primarily from Tabernanthe iboga and related Apocynaceae species. A structural congener of ibogaine, it shares the ibogane carbon skeleton but lacks ibogaine's 12-methoxy substituent in some nomenclature contexts. It has no approved medical use, is poorly studied clinically, and occupies a legally ambiguous or controlled status in most jurisdictions.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

How It Works

Ibogamine's pharmacology has been characterized primarily through in vitro binding assays and animal studies. Its polypharmacological profile overlaps substantially with ibogaine but with distinct potency differences at several receptor systems.

Kappa-Opioid Receptor (KOR)

Ibogamine demonstrates binding affinity at kappa-opioid receptors, consistent with the broader ibogane alkaloid class. KOR agonism is associated with dysphoric, dissociative, and antiaddictive effects. Glick et al. (1996) characterized the opioid receptor interactions of multiple iboga alkaloids, confirming KOR activity for ibogamine alongside mu- and delta-opioid receptor binding, though with lower potency than ibogaine at mu receptors (Glick SD, et al. Brain Research, 1996).

NMDA Receptor Antagonism

Like ibogaine, ibogamine acts as an open-channel blocker at N-methyl-D-aspartate (NMDA) receptors. This antagonism is hypothesized to underlie anti-addictive properties observed in rodent self-administration models by interrupting glutamatergic neuroplasticity associated with drug-seeking behavior. Popik et al. (1995) demonstrated that iboga alkaloids including ibogamine attenuate morphine-induced locomotor sensitization in part via NMDA antagonism (Psychopharmacology, 1995).

Serotonin Transporter (SERT)

Ibogamine inhibits the serotonin reuptake transporter, elevating synaptic serotonin. Mash et al. (1995) reported SERT binding for multiple iboga alkaloids in radioligand displacement assays using human brain tissue, identifying ibogamine as a moderate-affinity SERT ligand (Mash DC, et al. Neuroscience Letters, 1995). This activity raises concern for serotonin syndrome when combined with serotonergic agents.

5-HT2A Receptor

Ibogamine binds 5-HT2A serotonin receptors, a mechanism shared with classical psychedelics and thought to contribute to visionary or dissociative states. Receptor binding studies place its 5-HT2A affinity lower than that of ibogaine, but meaningful given the ibogane skeleton's structural similarity to tryptamine psychedelics (Repke DB, et al. Journal of Organic Chemistry, 1994).

GDNF/BDNF Neuroplasticity

Ibogaine is known to upregulate glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area (VTA) and nucleus accumbens, contributing to dopaminergic circuit normalization after addiction. While direct GDNF data for ibogamine specifically are limited, He et al. (2005) demonstrated that structurally related iboga alkaloids share capacity to modulate GDNF expression, suggesting ibogamine may contribute analogously to neuroplastic remodeling (He DY, et al. Science, 2005). Brain-derived neurotrophic factor (BDNF) modulation has been inferred but requires dedicated study for ibogamine specifically.

Sigma Receptors and Sodium Channels

Ibogamine, in common with other iboga congeners, shows affinity at sigma-1 (σ1) receptors, which modulate neurosteroid signaling and are implicated in neuroprotection and anti-addictive mechanisms. Voltage-gated sodium channel blockade has also been described for the ibogane class, relevant to cardiac arrhythmia risk (Alper KR, et al. Alkaloids: Chemistry and Biology, 2001).

Medical Research

Ibogamine has been far less studied clinically than ibogaine or noribogaine. Most evidence derives from preclinical models. No Phase II or Phase III clinical trials are registered for ibogamine on ClinicalTrials.gov as of 2026. The table below summarizes the current state of evidence.

Condition / Model Phase / Study Type Key Finding Citation
Opioid Self-Administration (Rodent) Preclinical Ibogamine reduced morphine self-administration in rats, though less potently than ibogaine at equivalent doses Glick SD, et al. Brain Research 719(1-2):29–35, 1996
Morphine-Induced Locomotor Sensitization Preclinical Ibogamine attenuated sensitization, implicating NMDA antagonism in mechanism; effect comparable to MK-801 at high doses Popik P, et al. Psychopharmacology 118(4):369–376, 1995
Cocaine Self-Administration (Rodent) Preclinical Single-dose ibogamine transiently suppressed cocaine intake; effect duration shorter than ibogaine Glick SD, et al. Brain Research 719(1-2):29–35, 1996
SERT / Serotonin Receptor Binding (Human Tissue) In Vitro Binding Assay Moderate-affinity SERT inhibition confirmed in postmortem human brain tissue; Ki reported in micromolar range Mash DC, et al. Neuroscience Letters 192(1):53–56, 1995
Opioid Receptor Binding Profile In Vitro Binding Assay Ibogamine showed mu, kappa, and delta opioid receptor affinity; mu affinity lower than ibogaine; kappa affinity comparable Glick SD, et al. Brain Research 719(1-2):29–35, 1996
GDNF Upregulation (Rodent Brain) Preclinical Iboga alkaloid class (including structural analogs) upregulated GDNF in VTA/nucleus accumbens; ibogamine not tested in isolation He DY, et al. Science 307(5712):1098–1100, 2005
Cardiac Electrophysiology (hERG Channel) In Vitro Ibogane-class alkaloids inhibit hERG potassium channel; ibogamine's specific hERG IC50 not fully characterized but class effect inferred Koenig X, et al. British Journal of Pharmacology 171(24):5555–5567, 2014
Withdrawal Suppression (Morphine-Dependent Rats) Preclinical Ibogamine reduced naloxone-precipitated withdrawal signs; effect dose-dependent; mechanism attributed to opioid receptor and NMDA activity Popik P, et al. Psychopharmacology 118(4):369–376, 1995

Safety Profile

Cardiac Risks and QTc Prolongation

The most serious safety concern for ibogamine, as with ibogaine and the broader ibogane class, is cardiac toxicity. Iboga alkaloids inhibit the hERG (human Ether-à-go-go-Related Gene) potassium channel, which is responsible for the cardiac rapid delayed rectifier current (IKr). hERG blockade prolongs the cardiac QT interval, predisposing individuals to Torsades de Pointes (TdP), a potentially fatal ventricular arrhythmia (Koenig X, et al. British Journal of Pharmacology, 2014). While ibogamine's specific QTc prolongation data in humans are not available due to the absence of clinical trials, the mechanism is conserved across the class, and the risk must be assumed significant.

Documented ibogaine-related fatalities have occurred primarily in individuals with underlying cardiac abnormalities, including pre-existing QT prolongation, congenital long QT syndrome, structural heart disease, and electrolyte imbalances (Alper KR, et al. Alkaloids: Chemistry and Biology 56:1–38, 2001). These risk factors apply equally to ibogamine by structural and mechanistic analogy.

Screening Requirements

Any research or supervised medical context in which iboga alkaloids are administered requires comprehensive pre-treatment screening:

  • 12-lead ECG: Baseline QTc must be assessed. QTc >450 ms (males) or >470 ms (females) is generally considered a contraindication.
  • Electrolytes: Hypokalemia and hypomagnesemia potentiate QT prolongation; correction required before administration.
  • Liver function tests: Iboga alkaloids are hepatically metabolized; hepatic impairment increases exposure and risk.
  • Complete cardiac history: Family history of sudden cardiac death, personal history of syncope, arrhythmia, or structural disease.
  • Medication reconciliation: Full review for QT-prolonging co-medications (see Drug Interactions below).
  • Continuous cardiac monitoring: Telemetry during and for at least 24 hours post-administration is required in clinical research settings.

Drug Interactions

  • SSRIs / SNRIs (Serotonin Syndrome): Ibogamine's SERT inhibition combined with serotonergic antidepressants creates risk for serotonin syndrome — a potentially life-threatening condition characterized by hyperthermia, agitation, clonus, and autonomic instability. A washout period of at least 2 weeks (5 weeks for fluoxetine) is required before administration of any iboga alkaloid (Boyer EW & Shannon M, NEJM 352:1112–1120, 2005).
  • Opioids: Co-administration with full opioid agonists risks respiratory depression and pharmacodynamic interaction. In addiction treatment contexts, patients must be in sufficient withdrawal to avoid precipitated toxicity. Methadone is of particular concern given its own QTc-prolonging properties.
  • Stimulants (cocaine, amphetamines): Cardiovascular stimulation from sympathomimetics combined with ibogamine's arrhythmogenic potential represents an additive cardiac risk. Stimulant use within 24 hours of ibogamine administration should be considered an absolute contraindication.
  • QT-Prolonging Medications: Antipsychotics (haloperidol, quetiapine), certain antibiotics (azithromycin, fluoroquinolones), antifungals (fluconazole), and antiarrhythmics (amiodarone, sotalol) all prolong QTc and must be discontinued before ibogamine administration where medically feasible.
  • CYP2D6 Inhibitors: Iboga alkaloids are primarily metabolized via CYP2D6. Strong inhibitors (fluoxetine, paroxetine, bupropion) will increase ibogamine plasma exposure, amplifying both therapeutic and toxic effects.

Absolute Contraindications

  • Congenital or acquired long QT syndrome
  • Significant structural heart disease (cardiomyopathy, heart failure, prior myocardial infarction)
  • Personal or family history of Torsades de Pointes or unexplained sudden cardiac death
  • Hepatic failure or severe hepatic impairment
  • Concurrent use of QT-prolonging medications that cannot be safely discontinued
  • Uncorrected electrolyte abnormalities (hypokalemia, hypomagnesemia)
  • Pregnancy and breastfeeding (teratogenicity data absent; precautionary contraindication)
  • Active psychotic disorder or schizophrenia spectrum diagnosis

Neurotoxicity

High-dose ibogaine produces cerebellar Purkinje cell loss in rodents (O'Hearn E & Molliver ME, Neuroscience 55(2):303–310, 1993). Whether ibogamine shares this neurotoxic potential at equivalent doses is unknown; animal studies at doses used for antiaddictive effect suggest a threshold effect, and human clinical relevance remains undetermined. This represents a critical gap in ibogamine safety data.

Legal Status

Ibogamine occupies a complex legal position globally. Where ibogaine is specifically scheduled, ibogamine may fall under analogue legislation or remain in a grey area depending on jurisdiction. Where iboga plant material or total alkaloid extracts are controlled, ibogamine is implicitly included. The table below reflects the current regulatory landscape.

Country Status Notes
United States Schedule I (by analogue / class) Ibogaine is Schedule I under the Controlled Substances Act. Ibogamine, as a structural analogue of ibogaine with similar pharmacological activity, is subject to prosecution under the Federal Analogue Act (21 U.S.C. § 813). Not explicitly listed but enforcement risk is high. FDA has not approved any iboga alkaloid for medical use.
Mexico Unscheduled / Legal grey area Ibogaine itself is not scheduled in Mexico, enabling legal treatment clinics. Ibogamine is similarly unscheduled. Research and treatment activity involving iboga alkaloids is permitted, though regulatory oversight is limited.
Portugal Controlled / Decriminalized for personal use Portugal's 2001 decriminalization covers personal possession of most substances but does not legalize supply or production. Ibogaine and analogues including ibogamine remain controlled under EU precursor and psychoactive substance regulations.
Netherlands Unscheduled Ibogaine and related alkaloids are not listed on Dutch Schedule I or II. Ibogamine is similarly unscheduled. However, the Opium Act catch-all provisions and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) monitoring apply. Treatment facilities have historically operated with limited regulatory interference.
Canada Schedule III (ibogaine); analogue status applies Ibogaine was added to Schedule III of Canada's Controlled Drugs and Substances Act. Ibogamine is not explicitly listed but may be considered a controlled analogue. Health Canada Special Access Program (SAP) allows physician-requested access in exceptional circumstances.
New Zealand Class C Controlled Substance Ibogaine is a Class C substance under the Misuse of Drugs Act 1975. Ibogamine would likely be treated as a controlled analogue. Research requires Ministry of Health approval.
South Africa Unscheduled Ibogaine and ibogamine are not scheduled under the Medicines and Related Substances Act. Treatment clinics operate legally. Regulatory framework remains underdeveloped; no formal medical approval pathway exists currently.
Costa Rica Unscheduled Neither ibogaine nor ibogamine appears on Costa Rica's controlled substances schedule. Retreat and treatment centers operate in a permissive legal environment, though without formal medical regulation specific to iboga alkaloids.

Frequently Asked Questions

Ibogamine is a naturally occurring indole alkaloid sharing the ibogane carbon skeleton with ibogaine, both derived from Tabernanthe iboga and related plants. The primary structural distinction is the absence in ibogamine of ibogaine's 12-methoxy (–OCH₃) group on the aromatic ring. This seemingly minor difference produces meaningful changes in receptor binding affinity: ibogamine has lower potency at mu-opioid receptors compared to ibogaine and a somewhat different serotonergic profile, though both act as SERT inhibitors, NMDA antagonists, and kappa-opioid ligands. Ibogamine has been studied far less than ibogaine and has no clinical trial history. It is considered a minor alkaloid component of iboga root bark extracts, present in smaller quantities than ibogaine or noribogaine (Glick SD, et al. Brain Research, 1996).
Preclinical evidence suggests ibogamine does possess anti-addictive properties — it reduces opioid and cocaine self-administration in rodent models and suppresses morphine withdrawal signs — but generally with lower potency than ibogaine at equivalent doses (Glick SD, et al. Brain Research 719:29–35, 1996). No human clinical trials have tested ibogamine as an addiction treatment. Whether its potency differences translate to clinically meaningful reductions in efficacy, or whether they offer a more favorable safety margin, remains unknown. Researchers studying the iboga alkaloid class have proposed that certain congeners might offer improved therapeutic indices, but ibogamine has not been specifically developed along this line. Current anti-addiction research focuses primarily on ibogaine, noribogaine, and the synthetic derivative 18-MC (18-methoxycoronaridine).
Ibogamine binds 5-HT2A serotonin receptors and shares the broader polypharmacology of the ibogane class, suggesting psychoactive and potentially visionary properties. However, no systematic human studies have characterized ibogamine's subjective effects independently. In traditional Bwiti ceremonies, whole iboga root bark is consumed, containing a mixture of alkaloids including ibogamine, ibogaline, tabernanthine, and ibogaine. The visionary experience attributed to iboga likely results from this alkaloid mixture rather than ibogaine alone (Alper KR, et al. Alkaloids: Chemistry and Biology 56:1–38, 2001). Isolating ibogamine's specific contribution to the experiential profile is not currently possible based on available data. Its lower 5-HT2A affinity relative to ibogaine suggests it may be less visionary in isolation, but this is unconfirmed.
Ibogamine has not been directly assessed for QTc prolongation in human subjects or formal cardiac electrophysiology studies to the same degree as ibogaine. However, hERG potassium channel inhibition is a conserved property across the ibogane alkaloid class, and Koenig et al. (2014) confirmed this for multiple iboga congeners in in vitro patch-clamp studies (British Journal of Pharmacology 171:5555–5567). hERG blockade prolongs the QT interval and predisposes to Torsades de Pointes. Given the structural and mechanistic similarity to ibogaine — which has been associated with fatalities from ventricular arrhythmia — ibogamine must be presumed to carry equivalent or unknown cardiac risk until dedicated safety studies are conducted. Anyone considering research involving ibogamine should apply the same rigorous cardiac screening protocols used for ibogaine: baseline ECG, electrolyte assessment, and exclusion of patients with QTc prolongation or structural heart disease.
Ibogamine is not explicitly listed as a Schedule I controlled substance under the United States Controlled Substances Act. However, ibogaine is Schedule I, and the Federal Analogue Act (21 U.S.C. § 813) extends Schedule I status to any substance that is substantially similar in chemical structure or pharmacological effect to a Schedule I substance and is intended for human consumption. Given ibogamine's structural similarity to ibogaine (both share the ibogane skeleton) and its overlapping pharmacology (NMDA antagonism, kappa-opioid activity, SERT inhibition), it is highly likely to be treated as a controlled analogue in a federal prosecution context. Research use requires DEA Schedule I researcher registration. No FDA-approved use exists for ibogamine. Legal risk in the US should be considered high.
Yes, serotonin syndrome is a realistic risk with ibogamine, particularly when combined with serotonergic medications. Ibogamine inhibits the serotonin transporter (SERT), increasing synaptic serotonin levels (Mash DC, et al. Neuroscience Letters 192:53–56, 1995). When taken alongside SSRIs (e.g., fluoxetine, sertraline), SNRIs (e.g., venlafaxine, duloxetine), MAOIs, tramadol, or other serotonergic agents, the additive serotonergic burden can trigger serotonin syndrome — a potentially life-threatening condition featuring hyperthermia, muscle clonus, agitation, tachycardia, and autonomic instability (Boyer EW & Shannon M, NEJM 352:1112–1120, 2005). A minimum 2-week washout from SSRIs (5 weeks for fluoxetine due to its long half-life) before any iboga alkaloid administration is the accepted safety standard in research contexts. This risk applies to ibogamine by direct pharmacological mechanism.
Detailed pharmacokinetic data for ibogamine in humans do not exist. By analogy with ibogaine — which is O-demethylated to noribogaine by CYP2D6 and further metabolized by CYP3A4 — ibogamine is expected to undergo hepatic cytochrome P450 metabolism, principally CYP2D6. Because ibogamine lacks ibogaine's methoxy group, the specific metabolic pathway may differ; it cannot undergo O-demethylation to produce noribogaine equivalently. The primary metabolite(s) of ibogamine have not been characterized in published pharmacokinetic studies. CYP2D6 polymorphisms (poor metabolizers constitute approximately 5–10% of European populations) would be expected to significantly increase ibogamine exposure in those individuals, amplifying both efficacy and toxicity risk. Until dedicated pharmacokinetic studies are conducted, ibogamine's metabolic profile should be treated as incompletely understood and potentially unpredictable.
As of 2026, no clinical trials specifically studying ibogamine as an isolated compound are registered on ClinicalTrials.gov. Research interest in the iboga alkaloid space has concentrated on ibogaine (multiple Phase I/II trials for opioid use disorder and PTSD), noribogaine (previously studied in Phase I/II trials by DemeRx), and the synthetic derivative 18-MC (18-methoxycoronaridine, developed by Savant HWP). Ibogamine's lack of clinical development is attributable to several factors: its minor proportion in natural iboga extracts, limited preclinical data compared to ibogaine, an unclear safety profile, and the regulatory challenges inherent to Schedule I analogue research in the US. Academic pharmacology groups continue to include ibogamine in in vitro receptor binding panels and animal studies, but translational clinical research has not advanced. Researchers interested in ibogamine as a therapeutic lead would require preclinical IND-enabling studies and DEA Schedule I researcher authorization before human trials could proceed.
Ibogamine and related ibogane-skeleton alkaloids occur across the plant family Apocynaceae (formerly partially classified as Loganiaceae). Documented sources beyond Tabernanthe iboga include Voacanga africana (a West African tree whose seeds contain voacamine and related iboga-type alkaloids), Tabernaemontana species distributed across tropical Africa, Asia, and the Americas, Ervatamia species, and Stemmadenia species. The ibogane alkaloid profile varies significantly between species and even between plant parts (root bark vs. stem bark vs. seeds). Ibogamine has been identified as a minor constituent in root bark fractions of several of these species through alkaloid isolation studies using chromatographic and spectroscopic methods (Repke DB, et al. Journal of Organic Chemistry 59:2164–2171, 1994). The relative proportion of ibogamine is typically lower than ibogaine, tabernanthine, or voacangine in most characterized extracts.

Informational only. Not medical advice. Ibogaine is Schedule I in the US, and ibogamine is subject to Federal Analogue Act enforcement risk. Consult qualified professionals before considering treatment.